{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:29:27Z","timestamp":1776727767216,"version":"3.51.2"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Limited information exists on the healthcare resource utilization (HCRU) associated with real-world natalizumab used as a first-line (1L) versus later-line (2L+) treatment in multiple sclerosis (MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe natalizumab use in newly diagnosed MS patients treated as 1L or 2L+ and evaluate unadjusted annualized relapse rates (ARR) and MS-related HCRU before and after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This retrospective observational study utilized Komodo Health Sentinel claims data from October 2015 to August 2022. The study included adults diagnosed with incident MS who initiated natalizumab treatment, with insurance coverage for at least 12\u2009months before diagnosis and 24\u2009months after. The index date was the first natalizumab claim on or after the diagnosis. Baseline was defined as the 365\u2009days prior to the index date, truncated at the time of diagnosis. Follow-up ended at the earliest occurrence of death, insurance disenrollment, treatment discontinuation (gap \u2a7e45\u2009days), switch to another disease-modifying therapy before natalizumab discontinuation, or study end.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Relapses and HCRU were assessed using person-time methods to account for varying follow-up times. Relapses were identified using a validated claims-based algorithm, and time to first relapse was analyzed using Kaplan\u2013Meier methods. Hazard ratios for relapse were estimated using univariate Cox models. Mean differences (MD) in HCRU between baseline and follow-up and between 1L and 2L+ treatment groups were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1174 patients in the 1L group (mean age 39.0, 72.0% female) and 394 in the 2L+ group (mean age 39.7, 79.4% female) were included. Patients in the 1L group had a significantly higher baseline ARR (1.48 vs 0.92,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and lower on-treatment ARR (0.28 vs 0.41 for 2L+,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). HCRU decreased significantly in the 1L group from baseline to follow-up: hospitalizations (MD 17.01\u2009visits\/year), length of stay (LOS; MD 20.96\u2009days\/year), emergency room visits (MD 9.83\u2009visits\/year), non-natalizumab outpatient visits (MD 12.11\u2009visits\/year) and long-term care facility stays (MD 22.18\u2009days\/year,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002). The 1L group showed greater reductions in inpatient visits (MD 10.01\u2009visits\/\/year), LOS (MD 16.73\u2009days\/year) and non-natalizumab outpatient visits (MD 11.64\u2009visits\/year) compared to the 2L+ group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Natalizumab as a first-line treatment was associated with greater reductions in ARR and MS-related HCRU compared to later-line use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251317949","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:21:26Z","timestamp":1742181686000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis"],"prefix":"10.1177","volume":"18","author":[{"given":"Robin L.","family":"Avila","sequence":"first","affiliation":[{"name":"Biogen,US Medical Rare Diseases, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-1834","authenticated-orcid":false,"given":"Nicole S.","family":"Croteau","sequence":"additional","affiliation":[{"name":"Cytel, Evidence, Value and Access, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Tang","sequence":"additional","affiliation":[{"name":"Cytel, Evidence, Value and Access, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-8043","authenticated-orcid":false,"given":"Jason C.","family":"Simeone","sequence":"additional","affiliation":[{"name":"Cytel, Evidence, Value and Access, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Jomaa","sequence":"additional","affiliation":[{"name":"Biogen, Value and Access \u2013 Global\/International Regions, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[{"name":"Biogen, NA Medical Evidence Generation, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Gianinazzi","sequence":"additional","affiliation":[{"name":"Biogen, Value and Market Access, Baar, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_3_5_2_2","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey GM","year":"2023","unstructured":"Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis 2023; 15: e1583.","journal-title":"WIREs Mech Dis"},{"key":"e_1_3_5_3_2","first-page":"94","article-title":"Does early-onset multiple sclerosis differ from adult-onset form in Iranian people","volume":"15","author":"Ashtari F","year":"2010","unstructured":"Ashtari F, Shaygannejad V, Farajzadegan Z, et al. Does early-onset multiple sclerosis differ from adult-onset form in Iranian people. J Res Med Sci 2010; 15: 94\u201399.","journal-title":"J Res Med Sci"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1532-1"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01570-0"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.09.002"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0728-3"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-6-530"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13692"},{"key":"e_1_3_5_11_2","article-title":"Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: a register-based prospective cohort study in Sweden","volume":"8","author":"Karampampa K","year":"2022","unstructured":"Karampampa K, Gyllensten H, Murley C, et al. Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: a register-based prospective cohort study in Sweden. Mult Scler J Exp Transl Clin 2022; 8: 20552173221092411.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330169"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.010"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104803"},{"key":"e_1_3_5_17_2","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz JM","year":"2019","unstructured":"Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2019; 7: e636.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18050940"},{"key":"e_1_3_5_19_2","article-title":"Impact of diagnosis and early treatment on the course of multiple sclerosis","volume":"19","author":"Noyes K","year":"2013","unstructured":"Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013; 19: s321\u2013s331.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.523670"},{"key":"e_1_3_5_22_2","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf DA","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002; 8: 469\u2013476.","journal-title":"J Manag Care Pharm"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.875456"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"e_1_3_5_25_2","unstructured":"Therneau T. A package for survival analysis in R. 2023 https:\/\/CRAN.R-project.org\/package=survival"},{"key":"e_1_3_5_26_2","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2021."},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.32614\/RJ-2021-053"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104216"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S55779"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S117962"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251317949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251317949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251317949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:04:57Z","timestamp":1767675897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251317949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":30,"alternative-id":["10.1177\/17562864251317949"],"URL":"https:\/\/doi.org\/10.1177\/17562864251317949","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"article-number":"17562864251317949"}}